<DOC>
	<DOCNO>NCT02289963</DOCNO>
	<brief_summary>Primary Objective : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab add-on therapy stable maximally tolerated daily statin therapy without lipid-modifying therapy ( LMT ) comparison placebo 24 week treatment South Korea Taiwan high cardiovascular risk patient hypercholesterolemia . Secondary Objectives : - To evaluate effect alirocumab comparison placebo LDL-C 12 week treatment . - To evaluate effect alirocumab lipid parameter : apolipoprotein B ( Apo B ) , non high density lipoprotein cholesterol ( non-HDL-C ) , total cholesterol ( TC ) , lipoprotein ( ) ( Lp [ ] ) , high density lipoprotein cholesterol ( HDL-C ) , triglyceride ( TGs ) , apolipoprotein A-1 ( Apo A-1 ) . - To evaluate safety tolerability alirocumab . - To evaluate development anti-alirocumab antibody .</brief_summary>
	<brief_title>Evaluation Alirocumab Addition Lipid-Modifying Therapy Patients With High Cardiovascular Risk Hypercholesterolemia South Korea Taiwan</brief_title>
	<detailed_description>The maximum study duration 35 week per patient , include 3 week screen period , 24 week randomize treatment period , 8 week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients hypercholesterolemia establish coronary heart disease ( CHD ) CHD risk equivalent adequately control maximally tolerate daily dose statin without LMT , stable dose least 4 week prior screen visit ( Week 3 ) . Exclusion criterion : Aged &lt; 18 year legal age adulthood , whichever great . Patients without establish CHD CHD risk equivalent . LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) patient history document cardiovascular disease . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) patient without history document cardiovascular disease . Not stable dose LMT ( include statin ) least 4 week prior screen visit ( Week 3 ) screen randomization visit . Currently take statin atorvastatin , rosuvastatin simvastatin . Atorvastatin , rosuvastatin simvastatin take daily take register dose . Daily dose atorvastatin 80 mg , rosuvastatin 20 mg simvastatin 40 mg. Fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) screening period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>